Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Products>This Product
  Products


Covance, Inc.

Product Description

Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, employees in more than 60 countries, and more than 11,000 employees worldwide.

Nonclinical Development: Toxicology, Research Products, Analytical Services

• Managed 443 compound development programs (>250 IND/CTA enabling), with  over 100 different sponsors, which led to 41 IND/CTA applications in 2009
• Performed best-in-class productivity cycle times: FIA to FIH in 22 weeks
• Dedicated Capacity Agreements with several major pharma customers
• Greater than 2.5M sq ft of research space

Clinical Development: Clinical Pharmacology, Clinical, Central Labs

• Supported 50% of latest breakthrough cancer treatments
• Supported development of the top 25 currently marketed medicines
• 70% of clinical programs on or ahead of enrollment timelines
• Broad-based, scalable and market-leading, Biomarker capability
• 99% of samples received within stability
• 145 million laboratory tests; 83,000 investigator sites; 100 countries
• Seven Clinical Pharmacology units with ~500 beds

Periapproval & Market Access

• Results-driven reimbursement support for >60% of the biologics market
• Designed and managed world’s largest safety registry ever – iPledge
• Team of experts dedicated to risk management and Pharmacovigilance
• Bi-coastal call center capabilities to deliver patient and physician support
Product Covance, Inc.
Company Covance - Service Directory
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Covance - Service Directory
210 Carnegie Center Princeton, New Jersey 08540 United States

Tel: +1.888.268.2623



Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!